Appendix Table C25. KQ1 Outcome VI. Thromboembolic complications: Darbepoetin versus control; definition for thromboembolic events as defined in journal publications

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Predefined definition** | **TE recorded** | **Other information reported** |
| **Hernandez 2009** | No | Yes | Adverse events were grouped by primary system organ class and preferred term within primary system organ class according to the Medical Dictionary for Regulatory Activities (MedDRA) dictionary (version 9.0). The frequency and percentage distributions of adverse events to study drug were summarized. Relation to study drug reported. |
| **Overgaard 2009** | No | No | In abstract only cardiovascular adverse events are reported. |
| **Pirker 2008** | No | Yes | Relation to treatment reported |
| **Vansteenkiste 2002** | No | Yes |  |
| **Untch 2011** | No | Yes |  |

TE: thromboembolic events